糖皮质激素与保激素药物单用或联用治疗IgG4相关性疾病:系统评价与网状Meta分析
该系统评价与网状Meta分析纳入15项研究共1169例IgG4-RD患者,比较糖皮质激素、免疫抑制剂和利妥昔单抗单用或联用的疗效与安全性。结果显示糖皮质激素联合免疫抑制剂较单药或利妥昔单抗诱导治疗有更高缓解率和更低复发率,利妥昔单抗维持治疗复发率最低,各组不良事件率相当。
要点
- 糖皮质激素联合免疫抑制剂较糖皮质激素单药降低复发率(OR=0.39,95%CI 0.20-0.80)。
- 糖皮质激素联合免疫抑制剂缓解率高于糖皮质激素、免疫抑制剂单药或利妥昔单抗诱导治疗。
- 利妥昔单抗维持治疗复发率最低(OR=0.10,95%CI 0.01-1.63),各组不良事件率相当。
核心结论
- 糖皮质激素联合免疫抑制剂治疗IgG4-RD患者与更高缓解率和更低复发率相关,且安全性特征与糖皮质激素、免疫抑制剂或利妥昔单抗诱导治疗相当。
- 利妥昔单抗维持治疗较糖皮质激素和免疫抑制剂有更大程度的复发率降低。
研究设计与样本
- 系统评价与网状Meta分析,检索相关数据库,纳入15项研究共1169例患者。
- 纳入研究为观察性设计,采用比值比(OR)及95%CI计算,并使用P-score对治疗进行排序。
主要发现
- 利妥昔单抗维持治疗在所有治疗中复发率最低(OR=0.10,95%CI 0.01-1.63)。
- 糖皮质激素联合免疫抑制剂较糖皮质激素单药复发率更低(OR=0.39,95%CI 0.20-0.80)。
- 糖皮质激素联合免疫抑制剂缓解率高于糖皮质激素单药(OR=3.36,95%CI 1.44-7.83)、免疫抑制剂单药(OR=55.31,95%CI 13.73-222.73)或仅利妥昔单抗诱导治疗(OR=7.38,95%CI 1.56-34.94)。
- 不同治疗组间不良事件发生率相当。
关键数值与推荐
- 复发率:利妥昔单抗维持治疗OR=0.10(95%CI 0.01-1.63);糖皮质激素联合免疫抑制剂对比糖皮质激素单药OR=0.39(95%CI 0.20-0.80)。
- 缓解率:糖皮质激素联合免疫抑制剂对比糖皮质激素单药OR=3.36(95%CI 1.44-7.83);对比免疫抑制剂单药OR=55.31(95%CI 13.73-222.73);对比仅利妥昔单抗诱导治疗OR=7.38(95%CI 1.56-34.94)。
临床怎么用
- 对于IgG4-RD患者,可考虑糖皮质激素联合免疫抑制剂以提高缓解率并降低复发率。
- 利妥昔单抗维持治疗可能进一步降低复发率,但需结合患者具体情况权衡。
局限性
- 纳入研究均为观察性设计,证据需谨慎解读。
- 需要更大样本的随机对照试验来确认上述结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the safety and efficacy of glucocorticoids (GCs), immunosuppressive agents (IM) and rituximab (RTX), alone or in combination, for the treatment of IgG4-RD. METHODS: Relevant articles published were searched in the databases with relevant key words. Network meta-analysis was conducted, with various outcomes including relapse rate, remission rate and adverse events. Data were calculated with odds ratio (ORs) and 95% CI. P-score was used to rank the treatments. RESULTS: A total of 15 studies involving 1169 patients were included. Network meta-analysis indicated that RTX maintenance therapy had the lowest relapse rate of all treatments (OR = 0.10, 95% CI [0.01, 1.63]), whereas GCs + IM was associated with a lower relapse rate compared with GCs alone (OR = 0.39, 95% CI [0.20, 0.80]). Further, patients treated with GCs + IM had a higher remission rate than those given GCs (OR= 3.36, 95% CI [1.44, 7.83]), IM (OR= 55.31, 95% CI [13.73, 222.73]) monotherapies or RTX induction therapy only (OR= 7.38, 95% CI [1.56, 34.94]). The rate of adverse events was comparable among the different treatment groups. CONCLUSION: Treatment of IgG4-RD patients with GCs and IM was associated with higher remission rates and lower relapse rates, as well as comparable safety profiles compared with GC, IM and RTX induction therapy. RTX maintenance therapy had a larger reduction in the relapse rate compared with GC and IM. The current evidence should be carefully scrutinized as the included studies were observational in design. Larger randomized controlled trials are needed to confirm.
引用
- Omar D, Chen Y, Cong Y, et al. Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: a systematic review and network meta-analysis. Rheumatology (Oxford). 2020. PMID: 31511884. doi:10.1093/rheumatology/kez380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。